Table of Contents
Chapter 1. Global Autologous Cell Therapy Market Executive Summary
1.1. Global Autologous Cell Therapy Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Application
1.3.2. By Source
1.3.3. By End-Use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Autologous Cell Therapy Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer's Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Autologous Cell Therapy Market Dynamics
3.1. Market Drivers
3.1.2. Rising Geriatric Population
3.1.3 Prevalence of Chronic Diseases
3.1.3. Technological Advancements and Innovation in Cell Therapies
3.2. Market Challenges
3.2.1. High Costs and Complex Manufacturing Processes
3.2.2. Stringent Regulatory Requirements
3.3. Market Opportunities
3.3.2. Increasing Investment and Research in Autologous Cell Therapies
3.3.3. Adoption of Personalized Medicine
Chapter 4. Global Autologous Cell Therapy Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Autologous Cell Therapy Market Size & Forecasts by Application 2022-2032
5.1. Segment Dashboard
5.2. Global Autologous Cell Therapy Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Cancer
5.2.2. Neurodegenerative Disorders
5.2.3. Cardiovascular Disorders
5.2.4. Autoimmune Disorders
5.2.5. Orthopedics
5.2.6. Wound Healing
5.2.7. Others
Chapter 6. Global Autologous Cell Therapy Market Size & Forecasts by Source 2022-2032
6.1. Segment Dashboard
6.2. Global Autologous Cell Therapy Market: Source Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Bone Marrow
6.2.2. Peripheral Blood
6.2.3. Adipose Tissue
6.2.4. Others
Chapter 7. Global Autologous Cell Therapy Market Size & Forecasts by End-Use 2022-2032
7.1. Segment Dashboard
7.2. Global Autologous Cell Therapy Market: End-Use Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Hospitals
7.2.2. Academics & Research
7.2.3. Others
Chapter 8. Global Autologous Cell Therapy Market Size & Forecasts by Region 2022-2032
8.1. North America Autologous Cell Therapy Market
8.1.1. U.S. Autologous Cell Therapy Market
8.1.1.1. Application breakdown size & forecasts, 2022-2032
8.1.1.2. Source breakdown size & forecasts, 2022-2032
8.1.1.3. End-Use breakdown size & forecasts, 2022-2032
8.1.2. Canada Autologous Cell Therapy Market
8.1.2.1. Application breakdown size & forecasts, 2022-2032
8.1.2.2. Source breakdown size & forecasts, 2022-2032
8.1.2.3. End-Use breakdown size & forecasts, 2022-2032
8.2. Europe Autologous Cell Therapy Market
8.2.1. UK Autologous Cell Therapy Market
8.2.1.1. Application breakdown size & forecasts, 2022-2032
8.2.1.2. Source breakdown size & forecasts, 2022-2032
8.2.1.3. End-Use breakdown size & forecasts, 2022-2032
8.2.2. Germany Autologous Cell Therapy Market
8.2.2.1. Application breakdown size & forecasts, 2022-2032
8.2.2.2. Source breakdown size & forecasts, 2022-2032
8.2.2.3. End-Use breakdown size & forecasts, 2022-2032
8.2.3. France Autologous Cell Therapy Market
8.2.3.1. Application breakdown size & forecasts, 2022-2032
8.2.3.2. Source breakdown size & forecasts, 2022-2032
8.2.3.3. End-Use breakdown size & forecasts, 2022-2032
8.2.4. Spain Autologous Cell Therapy Market
8.2.4.1. Application breakdown size & forecasts, 2022-2032
8.2.4.2. Source breakdown size & forecasts, 2022-2032
8.2.4.3. End-Use breakdown size & forecasts, 2022-2032
8.2.5. Italy Autologous Cell Therapy Market
8.2.5.1. Application breakdown size & forecasts, 2022-2032
8.2.5.2. Source breakdown size & forecasts, 2022-2032
8.2.5.3. End-Use breakdown size & forecasts, 2022-2032
8.2.6. Rest of Europe Autologous Cell Therapy Market
8.2.6.1. Application breakdown size & forecasts, 2022-2032
8.2.6.2. Source breakdown size & forecasts, 2022-2032
8.2.6.3. End-Use breakdown size & forecasts, 2022-2032
8.3. Asia-Pacific Autologous Cell Therapy Market
8.3.1. China Autologous Cell Therapy Market
8.3.1.1. Application breakdown size & forecasts, 2022-2032
8.3.1.2. Source breakdown size & forecasts, 2022-2032
8.3.1.3. End-Use breakdown size & forecasts, 2022-2032
8.3.2. India Autologous Cell Therapy Market
8.3.2.1. Application breakdown size & forecasts, 2022-2032
8.3.2.2. Source breakdown size & forecasts, 2022-2032
8.3.2.3. End-Use breakdown size & forecasts, 2022-2032
8.3.3. Japan Autologous Cell Therapy Market
8.3.3.1. Application breakdown size & forecasts, 2022-2032
8.3.3.2. Source breakdown size & forecasts, 2022-2032
8.3.3.3. End-Use breakdown size & forecasts, 2022-2032
8.3.4. Australia Autologous Cell Therapy Market
8.3.4.1. Application breakdown size & forecasts, 2022-2032
8.3.4.2. Source breakdown size & forecasts, 2022-2032
8.3.4.3. End-Use breakdown size & forecasts, 2022-2032
8.3.5. South Korea Autologous Cell Therapy Market
8.3.5.1. Application breakdown size & forecasts, 2022-2032
8.3.5.2. Source breakdown size & forecasts, 2022-2032
8.3.5.3. End-Use breakdown size & forecasts, 2022-2032
8.3.6. Rest of Asia Pacific Autologous Cell Therapy Market
8.3.6.1. Application breakdown size & forecasts, 2022-2032
8.3.6.2. Source breakdown size & forecasts, 2022-2032
8.3.6.3. End-Use breakdown size & forecasts, 2022-2032
8.4. Latin America Autologous Cell Therapy Market
8.4.1. Brazil Autologous Cell Therapy Market
8.4.1.1. Application breakdown size & forecasts, 2022-2032
8.4.1.2. Source breakdown size & forecasts, 2022-2032
8.4.1.3. End-Use breakdown size & forecasts, 2022-2032
8.4.2. Mexico Autologous Cell Therapy Market
8.4.2.1. Application breakdown size & forecasts, 2022-2032
8.4.2.2. Source breakdown size & forecasts, 2022-2032
8.4.2.3. End-Use breakdown size & forecasts, 2022-2032
8.4.3. Rest of Latin America Autologous Cell Therapy Market
8.4.3.1. Application breakdown size & forecasts, 2022-2032
8.4.3.2. Source breakdown size & forecasts, 2022-2032
8.4.3.3. End-Use breakdown size & forecasts, 2022-2032
8.5. Middle East & Africa Autologous Cell Therapy Market
8.5.1. Saudi Arabia Autologous Cell Therapy Market
8.5.1.1. Application breakdown size & forecasts, 2022-2032
8.5.1.2. Source breakdown size & forecasts, 2022-2032
8.5.1.3. End-Use breakdown size & forecasts, 2022-2032
8.5.2. South Africa Autologous Cell Therapy Market
8.5.2.1. Application breakdown size & forecasts, 2022-2032
8.5.2.2. Source breakdown size & forecasts, 2022-2032
8.5.2.3. End-Use breakdown size & forecasts, 2022-2032
8.5.3. Rest of Middle East & Africa Autologous Cell Therapy Market
8.5.3.1. Application breakdown size & forecasts, 2022-2032
8.5.3.2. Source breakdown size & forecasts, 2022-2032
8.5.3.3. End-Use breakdown size & forecasts, 2022-2032
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1 Company 1
9.1.2 Company 2
9.1.3 Company 3
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. BrainStorm Cell Therapeutics
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Holostem Terapie Avanzate S.R.L
9.3.3. Pharmicell Co. Inc
9.3.4. Opexa Therapeutics
9.3.5. Caladrius Biosciences Inc
9.3.6. U.S. Stem Cell Inc
9.3.7. Lonza
9.3.8. Bristol Myers Squibb
9.3.9. Novartis
9.3.10. Autolus Therapeutics
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes